Cullinan Therapeutics to Participate in Fireside Chat at the Citi 2026 Virtual Oncology Leadership Summit
Rhea-AI Summary
Cullinan Therapeutics (Nasdaq: CGEM) will participate in a fireside chat at the Citi 2026 Virtual Oncology Leadership Summit on Thursday, February 19, 2026 at 10:00 a.m. ET. Speakers include CEO Nadim Ahmed and CMO Jeffrey Jones, M.D., M.B.A.
A live webcast will be available under the Events and Presentations section of the company’s investor relations website: https://investors.cullinantherapeutics.com/events.
Positive
- None.
Negative
- None.
News Market Reaction – CGEM
In the Feb 18 session, CGEM gained 2.05%, reflecting a moderate positive market reaction. Argus tracked a peak move of +10.4% during that session. Our momentum scanner triggered 31 alerts that day, indicating elevated trading interest and price volatility. Trading volume was above average at 1.9x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 05 | Conference appearance | Neutral | -3.9% | Management fireside chat at Guggenheim Emerging Outlook: Biotech Summit 2026. |
| Jan 08 | Corporate update | Positive | +1.8% | 2026 pipeline milestones and cash runway update highlighting $439.0M liquidity. |
| Dec 08 | Clinical data update | Positive | +17.5% | Updated Phase 1 CLN-049 AML data with meaningful response rates and durability. |
| Dec 01 | Regulatory designation | Positive | -5.5% | FDA Fast Track designation for CLN-049 in relapsed/refractory AML. |
| Nov 20 | Regulatory filing | Positive | +3.2% | Initiation of rolling NDA submission for zipalertinib in EGFR ex20ins NSCLC. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Positive clinical and regulatory updates have often seen aligned positive moves, while some regulatory wins showed near-term negative reactions.
Over the past few months, Cullinan reported several major milestones. A Nov 20, 2025 NDA rolling submission for zipalertinib and a Dec 1, 2025 FDA Fast Track designation for CLN-049 underscored regulatory progress. Updated CLN-049 data on Dec 8, 2025 drove a strong positive move. A Jan 8, 2026 corporate update highlighted 2026 clinical catalysts and a $439.0 million cash position, followed by conference participation news on Feb 5, 2026. Today’s conference appearance continues this investor-relations cadence.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today announced that Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Citi 2026 Virtual Oncology Leadership Summit on Thursday, February 19, 2026, at 10:00 a.m. ET.
A webcast of the fireside chat will be available under the Events and Presentations section of the Company’s investor relations website at https://investors.cullinantherapeutics.com/events.
About Cullinan Therapeutics
Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a biopharmaceutical company developing potential first- or best-in-class, high-impact therapies for autoimmune diseases and cancer. Cullinan pursues promising therapeutic targets while leveraging core expertise in T cell engagers, which are established in oncology and are now advancing into autoimmune diseases. With a clinical-stage pipeline built on a rigorous scientific approach and purposeful innovation, Cullinan is advancing its mission to deliver new standards of care for patients. Learn more about Cullinan at https://cullinantherapeutics.com/, and follow Cullinan on LinkedIn and X.
Contacts:
Investors
Nick Smith
+1 401.241.3516
nsmith@cullinantx.com
Media
Rose Weldon
+1 215.801.7644
rweldon@cullinantx.com
